Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
LuciA-15 - a real-world prospective study of PARP inhibitors for the treatment of patients with HER-2 negative metastatic breast cancer with germline and/or somatic mutation of BRCA genes or homologous recombination repair related genes.
Petracci FE, Villarreal-Garza C, Argañaraz F, Abuin GG, Peñaloza J, Flores MA, Piazzoni L, Riggi C, Fabiano L, González L, Cieplinski B, Rivero S, Korbenfeld E, Mandó P. Petracci FE, et al. Ecancermedicalscience. 2023 Nov 21;17:1634. doi: 10.3332/ecancer.2023.1634. eCollection 2023. Ecancermedicalscience. 2023. PMID: 38414929 Free PMC article.
The Emerging Role of Tertiary Lymphoid Structures in Breast Cancer: A Narrative Review.
Narvaez D, Nadal J, Nervo A, Costanzo MV, Paletta C, Petracci FE, Rivero S, Ostinelli A, Freile B, Enrico D, Pombo MT, Amat M, Aguirre ED, Chacon M, Waisberg F. Narvaez D, et al. Among authors: petracci fe. Cancers (Basel). 2024 Jan 17;16(2):396. doi: 10.3390/cancers16020396. Cancers (Basel). 2024. PMID: 38254885 Free PMC article. Review.
Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline.
Al Sukhun S, Temin S, Barrios CH, Antone NZ, Guerra YC, Chavez-MacGregor M, Chopra R, Danso MA, Gomez HL, Homian NM, Kandil A, Kithaka B, Koczwara B, Moy B, Nakigudde G, Petracci FE, Rugo HS, El Saghir NS, Arun BK. Al Sukhun S, et al. Among authors: petracci fe. JCO Glob Oncol. 2024 Jan;10:e2300285. doi: 10.1200/GO.23.00285. JCO Glob Oncol. 2024. PMID: 38206277 Free PMC article.
Hormone Receptor-Positive / HER2-Negative Early Breast Cancer High-Risk Population: An Algorithm for Optimization Systemic Adjuvant Treatment Based on 2022 Updates.
González-Hurtado D, Rivero S, Samamé Pérez-Vargas JC, Petracci FE. González-Hurtado D, et al. Among authors: petracci fe. Breast Cancer (Auckl). 2023 Aug 23;17:11782234231192780. doi: 10.1177/11782234231192780. eCollection 2023. Breast Cancer (Auckl). 2023. PMID: 37637230 Free PMC article. Review.
Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2.
Narváez D, Waisberg F, Soulé T, Angel M, Bruno L, Girotti MR, Pupareli C, Chacón M, Petracci FE. Narváez D, et al. Among authors: petracci fe. Ecancermedicalscience. 2022 Sep 26;16:1448. doi: 10.3332/ecancer.2022.1448. eCollection 2022. Ecancermedicalscience. 2022. PMID: 36405946 Free PMC article.